![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cance... GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.09 | -3.21428571429 | 2.8 | 2.87 | 2.69 | 8988 | 2.74448478 | CS |
4 | -0.09 | -3.21428571429 | 2.8 | 2.96 | 2.62 | 17530 | 2.78449072 | CS |
12 | -0.66 | -19.5845697329 | 3.37 | 10.6599 | 2.6 | 1554239 | 7.16319955 | CS |
26 | -3.644 | -57.3497009758 | 6.354 | 10.6599 | 2.6 | 718843 | 7.11850909 | CS |
52 | -5.96 | -68.7427912341 | 8.67 | 10.6599 | 2.6 | 429373 | 7.20575115 | CS |
156 | -352.79 | -99.2376933896 | 355.5 | 363.6 | 2.6 | 293306 | 48.05027674 | CS |
260 | -162.29 | -98.3575757576 | 165 | 591.993 | 2.6 | 327746 | 108.78518853 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions